The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C

Journal of the Formosan Medical Association

Ming-Yen Hsieh¹  Yu-Sheng Zeng²  Wan-Yi Hsu²  Pei-Chin Lin²  Po-Cheng Liang³  Shyh-Shin Chiou³  Ching-I. Huang³  Ming-Lung Yu⁴  Ming-Lun Yeh⁴  Chung-Feng Huang⁴  Wan-Long Chuang⁴  Zu-Yau Lin⁴  Jee-Fu Huang⁴  Chia-Yen Dai⁴  Shinn-Cherng Chen⁴ 

[1] Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;Division of Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;Graduate Institute of Clinical Medicine College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;

关键词: Hepatitis C;    Thalassemia;    Interferon;    Interleukin-28B;    Anemia;    Blood transfusion;   

DOI  :  10.1016/j.jfma.2017.10.001

来源: DOAJ

【 授权许可】

Unknown